Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Humanigen Inc
(NQ:
HGEN
)
0.0361
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Humanigen Inc
< Previous
1
2
3
4
Next >
Humanigen Inc. Added to Russell 3000(R) Index
June 28, 2021
Burlingame, California--(Newsfile Corp. - June 28, 2021) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing...
Via
Newsfile
Topics
Derivatives
Regulatory Compliance
Exposures
COVID-19
Derivatives
Legal
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)
June 14, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations
June 07, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen to Present at the 2021 LD Micro Invitational XI
June 03, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
May 28, 2021
From
Humanigen, Inc.
Via
Business Wire
GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021
May 26, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen to Present at Jefferies Healthcare Conference
May 19, 2021
From
Humanigen, Inc
Via
Business Wire
Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
May 17, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Reports First Quarter 2021 Financial Results
May 13, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients
May 05, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer
April 21, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
April 19, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
April 09, 2021
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Closing of Public Offering of Common Stock
April 06, 2021
From
Humanigen, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.